<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">255</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2020-7-1-32-37</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Inhibin B in stromal-cell ovarian tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Ингибин В при стромально-клеточных опухолях яичников</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0430-2754</contrib-id><name-alternatives><name xml:lang="en"><surname>Lyubimova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Любимова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><bold>Нина Васильевна Любимова </bold></p><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><email>biochimia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4915-2219</contrib-id><name-alternatives><name xml:lang="en"><surname>Beishembaev</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Бейшембаев</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="KG">Kyrgyzstan</country></address><bio xml:lang="en"><p><italic>144a Bokonbaeva St., Bishkek 720064</italic></p></bio><bio xml:lang="ru"><p><italic>720064 Бишкек, ул. Боконбаева, 144а</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Timofeev</surname><given-names>Yu. S.</given-names></name><name xml:lang="ru"><surname>Тимофеев</surname><given-names>Ю. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3898-4127</contrib-id><name-alternatives><name xml:lang="en"><surname>Kushlinskii</surname><given-names>N. E.</given-names></name><name xml:lang="ru"><surname>Кушлинский</surname><given-names>Н. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">S.B. Daniyarova Kyrgyz State Medical Institute for Retraining and Further Training, Ministry of Health of the Kyrgyz Republic</institution></aff><aff><institution xml:lang="ru">Кыргызский государственный медицинский институт переподготовки и повышения квалификации им. С. Б. Даниярова Минздрава Кыргызской Республики</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2020</year></pub-date><volume>7</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>37</lpage><history><date date-type="received" iso-8601-date="2020-03-29"><day>29</day><month>03</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-03-29"><day>29</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Lyubimova N.V., Beishembaev A.M., Timofeev Y.S., Kushlinskii N.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Любимова Н.В., Бейшембаев А.М., Тимофеев Ю.С., Кушлинский Н.Е.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Lyubimova N.V., Beishembaev A.M., Timofeev Y.S., Kushlinskii N.E.</copyright-holder><copyright-holder xml:lang="ru">Любимова Н.В., Бейшембаев А.М., Тимофеев Ю.С., Кушлинский Н.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/255">https://umo.abvpress.ru/jour/article/view/255</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Tumors of stroma of the sex cord include a family of tumors that are diverse in structure and biological characteristics, including hormone-active ovarian tumors, such as granulosa cell tumor (GCT) of the ovary and a tumor from Sertoli–Leydig cells. For these types of tumors, of particular importance is the analysis of biochemical markers, among which the most promising is inhibin B.</p><p><bold>The objective of the study.</bold> Comparative analysis of inhibin B levels in the blood serum of patients with stromal cell tumors and other types malignancies.</p><p><bold>Materials and methods.</bold> 64 patients with primary ovarian tumors were examined: 31 – GCT of the ovary, 16 – tumors from Sertoli–Leydig cells, 17 – adenocarcinomas. Comparison group – 20 patients with malignant tumors of other localizations, control – 74 healthy women and 37 patients with benign ovarian tumors. Inhibin B was determined in blood serum using the standardized Inhibin B Gen II ELISA (Beckman Coulter, USA) immunoassay.</p><p><bold>Results.</bold> The analysis of inhibin B levels in last days of the luteal phase, show an increase of marker level in patients with GCT and tumors from Sertoli–Leydig cells, while in ovarian adenocarcinomas and malignant tumors of other locations inhibin B secretion doesn’t differ from the control. The sensitivity of inhibin B in diagnostics of GCT was 93.5 %, in tumor from Sertoli–Leydig cells – 81.3 % with specificity – 100 %.</p><p><bold>Conclusion.</bold> Inhibin B is an effective biomarker of GCT and ovarian tumors from Sertoli–Leydig cells, which results must be interpreted according the functional state of the ovaries.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> К опухолям стромы полового тяжа относится семейство разных по строению и биологическим особенностям опухолей, включая гормонально-активные опухоли яичников, такие как гранулезоклеточная опухоль яичника (ГКОЯ) и опухоль яичника из клеток Сертоли–Лейдига. Для данных типов опухолей особенное значение имеет анализ биохимических маркеров, к одним из самых перспективных относится ингибин B.</p><p><bold>Цель исследования</bold> – сравнительный анализ сывороточных уровней ингибина В у больных со стромально-клеточными опухолями и другими типами злокачественных новообразований.</p><p><bold>Материалы и методы.</bold> Обследованы 64 женщины с первичными опухолями яичников (31 – ГКОЯ, 16 – опухоль из клеток Сертоли–Лейдига, 17 – аденокарцинома). Группу сравнения составили 20 больных со злокачественными опухолями других локализаций, контрольную группу – 74 женщины без онкологических заболеваний и 37 больных с доброкачественными неоплазиями яичников. Определение уровня ингибина B в сыворотке крови проводили с использованием стандартизованного иммуноферментного набора Inhibin B Gen II ELISA (Beckman Coulter, США).</p><p><bold>Результаты.</bold> При анализе уровня ингибина В выявлено его повышение при ГКОЯ и опухолях из клеток Сертоли–Лейдига, тогда как при аденокарциномах яичника и злокачественных опухолях других локализаций секреция ингибина B не отличалась от таковой в контрольной группе. Чувствительность ингибина В в диагностике ГКОЯ составила 93,5 %, при опухоли из клеток Сертоли–Лейдига – 81,3 % при специфичности по контролю 100 %.</p><p><bold>Заключение.</bold> Ингибин B – высокоэффективный биомаркер ГКОЯ и опухолей яичников из клеток Сертоли–Лейдига, при анализе уровня которого следует учитывать функциональный статус яичников.</p></trans-abstract><kwd-group xml:lang="en"><kwd>inhibin B</kwd><kwd>granulosa cell tumor of the ovary</kwd><kwd>a tumor from Sertoli–Leydig cells</kwd><kwd>biochemical marker</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ингибин В</kwd><kwd>гранулезоклеточная опухоль яичника</kwd><kwd>опухоль из клеток Сертоли–Лейдига</kwd><kwd>биохимический маркер</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bryk S., Farkkila A., Bützow R. et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. Int J Gynecol Cancer 2015;25(1):33–41. DOI: 10.1097/IGC.0000000000000304.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Davydov M.I. Lectures on gynecological oncology. Moscow: MEDpress-inform, 2009. Pp. 288–322. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Давыдов М.И. Лекции по онкогинекологии. М.: МЕДпресс-информ, 2009. С. 288–322.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Kozachenko V.P. Sex cord stromal tumors. Onkoginekologiya = Oncogynecology 2015;(4):41–7. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Козаченко В.П. Опухоли стромы полового тяжа. Онкогинекология 2015;(4):41–7.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Liang L., Menzin A., Lovecchio J.L., Navarro M.D. Ovarian Sertoli-Leydig cell tumor with predominant heterologous mucinous differentiation and foci of hepatocytic differentiation: case report and review of the literature. Ann Clin Lab Sci 2015;45(3):348–51.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Tretarre B., Molinie F., Woronoff A.S. et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980– 2012. Gynecol Oncol 2015;139(2):324–9. DOI: 10.1016/j.ygyno.2015.09.013.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Seagle B.L., Ann P., Butler S., Shahabi S. Ovarian granulosa cell tumor: A National Cancer Database study. Gynecol Oncol 2017;146(2):285–91.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Levin G., Zigron R., Haj-Yahya R. et al. Granulosa cell tumor of ovary: A systematic review of recent evidence. Eur J Obstet Gynecol Reprod Biol 2018;225:57–61. DOI: 10.1016/j.ejogrb.2018.04.002.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Rey R., Sabourin J.C., Venara M. et al. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000;31(10):1202–8. DOI: 10.1053/hupa.2000.18498.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Robertson D.M., Stephenson T., Pruysers E. et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 2002;191(1):97–103. DOI: 10.1016/s0303-7207(02)00060-6.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Färkkilä A., Haltia U.M., Tapper J. et al. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 2017;49(5):435–47. DOI: 10.1080/07853890.2017.1294760.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Cherepanova E.V., Laktionov K.P., Anurova O.A. et al. Clinical and morphological features of ovarian tumors from Sertoli–Leydig cells. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of the Female Reproductive System 2010;(4):83–8. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Черепанова Е.В., Лактионов К.П., Анурова О.А. и др. Клинико-морфологические особенности опухолей яичников из клеток Сертоли–Лейдига. Опухоли женской репродуктивной системы 2010;(4):83–8.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Alam K., Maheshwari V., Rashid S. et. al. Bilateral Sertoli–Leydig cell tumor of the ovary: a rare case report. Indian J Pathol Microbiol 2009;52(1):97–9. DOI: 10.4103/0377-4929.44981.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cabrera-Cantu F., Urrutia-Osorio M., Valdez-Arellano F. et al. Sertoli–Leydig cell tumor in a 12-year-old girl: a review article and case report. Arch Gynecol Obstet 2014;290(4):791–6. DOI: 10.1007/s00404-014-3293-6.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Schneider D.T., Orbach D., Cecchetto G. et al. Ovarian Sertoli–Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51(4):543–50. DOI: 10.1016/j.ejca.2014.11.013.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Burger H.G., Robertson D.M., Cahir N. et al. Caracterization of inhibin immunoreactivity in post-menopausal women with ovarian tumors. Clin Endocrinol 1996;44(4):413–8. DOI: 10.1046/j.1365-2265.1996.627450.x.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Burger H.G., Fuller P.J., Chu S. et al. The inhibins and ovarian cancer. Mol Cell Endocrinol 2001;180(1–2):145–8. DOI: 10.1016/s0303-7207(01)00519-6.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Groome N.P., Illingworth P.J., O’Brien M. et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81(4):1401–5. DOI: 10.1210/jcem.81.4.8636341.</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Beishembaev A.M., Lyubimova N.V., Abaev V.M. et al. The use of inhibin B in relapses of granulosa cell tumors of the ovaries. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of the Female Reproductive System 2010;(3): 68–72. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Бейшембаев А.М., Любимова Н.В., Абаев В.М. и др. Применение ингибина В при рецидивах гранулезоклеточных опухолей яичников. Опухоли женской репродуктивной системы 2010;(3):68–72.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Lyubimova N.V., Beishembaev A.M., Kushlinskii D.N. etal. Granulosa cell tumors of the ovary and inhibin B. Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2010;150(11): 567–70. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Любимова Н.В., Бейшембаев А.М., Кушлинский Д.Н. и др. Гранулезоклеточные опухоли яичников и ингибин В. Бюллетень экспериментальной биологии и медицины 2010;150(11):567–70.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Zhordania K.I., Kerzhkovskaya N.S., Payanidi U.G. et al. Granulosa cell tumors of the ovary. Onkoginekologiya = Oncogynecology 2014;(2):33–41. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Жорданиа К.И., Кержковская Н.С., Паяниди Ю.Г. и др. Гранулезоклеточные опухоли яичника. Диагностика и лечение. Онкогинекология 2014;(2):33–41.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Haltia U.M., Hallamaa M., Tapper J. et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors. Gynecol Oncol 2017;144(1):83–9. DOI: 10.1016/j.ygyno.2016.11.018.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mom C.H., Engelen M.J., Willemse P.H. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center. Gynecol Oncol 2007;105(2):365–72. DOI: 10.1016/j.ygyno.2006.12.034.</mixed-citation></ref></ref-list></back></article>
